Comparing Valuation And Performance: Sorrento Therapeutics, Inc. (SRNE), Heron Therapeutics, Inc. (HRTX)

The shares of Sorrento Therapeutics, Inc. have increased by more than 100.00% this year alone. The shares recently went up by 3.40% or $0.25 and now trades at $7.60. The shares of Heron Therapeutics, Inc. (NASDAQ:HRTX), has jumped by 69.89% year to date as of 05/11/2018. The shares currently trade at $30.75 and have been able to report a change of -3.30% over the past one week.

The stock of Sorrento Therapeutics, Inc. and Heron Therapeutics, Inc. were two of the most active stocks on Friday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.

Next 5Y EPS Growth: 37.00% versus 18.90%

When a company is able to grow consistently in terms of earnings at a high compound rate have the highest likelihood of creating value for its shareholders over time. Analysts have predicted that SRNE will grow it’s earning at a 37.00% annual rate in the next 5 years. This is in contrast to HRTX which will have a positive growth at a 18.90% annual rate. This means that the higher growth rate of SRNE implies a greater potential for capital appreciation over the years.

Profitability and Returns

Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. The ROI of SRNE is 27.40% while that of HRTX is -121.80%. These figures suggest that SRNE ventures generate a higher ROI than that of HRTX.

Cash Flow

The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, SRNE’s free cash flow per share is a negative -0.02, while that of HRTX is also a negative -0.23.

Liquidity and Financial Risk

The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The current ratio for SRNE is 0.70 and that of HRTX is 1.90. This implies that it is easier for SRNE to cover its immediate obligations over the next 12 months than HRTX. The debt ratio of SRNE is 0.03 compared to 0.31 for HRTX. HRTX can be able to settle its long-term debts and thus is a lower financial risk than SRNE.


SRNE currently trades at a P/B of 2.75, and a P/S of 4.52 while HRTX trades at a P/B of 21.65, and a P/S of 56.52. This means that looking at the earnings, book values and sales basis, SRNE is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.

Analyst Price Targets and Opinions

The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of SRNE is currently at a -69.6% to its one-year price target of 25.00. Looking at its rival pricing, HRTX is at a -24% relative to its price target of 40.46.

When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), SRNE is given a 1.50 while 1.70 placed for HRTX. This means that analysts are more bullish on the outlook for HRTX stocks.

Insider Activity and Investor Sentiment

Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for SRNE is 4.65 while that of HRTX is just 6.57. This means that analysts are more bullish on the forecast for SRNE stock.


The stock of Heron Therapeutics, Inc. defeats that of Sorrento Therapeutics, Inc. when the two are compared, with HRTX taking 2 out of the total factors that were been considered. HRTX happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, HRTX is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for HRTX is better on when it is viewed on short interest.

Previous ArticleNext Article

Related Post

Choosing Between Huntsman Corporation (HUN) and FM... Huntsman Corporation (NYSE:HUN) shares are up more than 61.95% this year and recently decreased -2.06% or -$0.65 to settle at $30.90. FMC Corporation ...
Dissecting the Numbers for PPL Corporation (PPL) a... PPL Corporation (NYSE:PPL) shares are up more than 0.48% this year and recently increased 2.74% or $0.83 to settle at $31.10. Deere & Company (NYS...
Iovance Biotherapeutics, Inc. (IOVA) vs. Alexion P... Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares are up more than 83.12% this year and recently increased 27.39% or $3.15 to settle at $14.65. Alexi...
Taking Tally Of Encana Corporation (ECA), Sequans ... The shares of Encana Corporation have increased by more than 0.90% this year alone. The shares recently went up by 2.44% or $0.32 and now trades at $1...
Hewlett Packard Enterprise Company (HPE) vs. Pulte... Hewlett Packard Enterprise Company (NYSE:HPE) shares are up more than 25.28% this year and recently increased 2.04% or $0.36 to settle at $17.99. Pult...